EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Published Version | doi:10.1186/1129-2377-15-S1-G10 |
| Citable link      | http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347502 |
| Terms of Use      | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
MEETING ABSTRACT

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

P Goadsby1*, D Dodick2, E Spierings3, J Scherer4, S Sweeney5, D Grayzel5

From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark. 18-21 September 2014

Introduction
Migraine remains poorly treated with few effective preventive medications available.

Aim
We evaluated the efficacy and safety of LY2951742, a fully humanized monoclonal antibody to Calcitonin Gene-Related Peptide (CGRP) for migraine prevention.

Methods
Eligible subjects with 4-14 migraine headache days (MHD) per month were randomized in a double-blind manner to LY2951742 or placebo, administered subcutaneously, every other week over a 12-week period. The primary endpoint was the mean change from baseline in number of MHD in the last 28 day period (month three); secondary endpoints included the mean change in headache days, migraine attacks, and the 50% responder rate at month 3.

Results
Mean change in MHD (primary) was -4.2 vs. -3.0 for LY2951742 (n=107) and placebo (n=110), respectively (p = 0.003). LY2951742 was superior to placebo for all secondary endpoints including headache days -4.9 vs. -3.7 (p = 0.0117), migraine attacks -3.1 vs. -2.3 (p = 0.0051), and 50% responder rate, 70% vs. 45% (OR 2.88 [CI 1.78;4.69]). An exploratory endpoint of complete response (100% reduction in MHD in month 3) was 31.6% vs. 17.3% (OR 2.16 [CI 1.24;3.75]) for LY2951742 and placebo, respectively. Adverse events reported by approximately ≥5% of LY2951742-treated patients and more frequently with LY2951742 than placebo included upper respiratory tract infections, injection site pain, neck pain, abdominal pain, dizziness, injection site erythema, rash, hypertension and pain in extremity.

Conclusions
Treatment with LY2951742 demonstrated significant separation from placebo on the primary and secondary endpoints. LY2951742 appeared to be safe and well-tolerated.

Authors’ details
1NIHR-Wellcome Trust Clinical Research Facility (KCL) and Dept. of Neurology (UCSF), King’s College London and Univ. of California - San Francisco, London, UK 2Dept. of Neurology, Mayo Clinic, Phoenix, USA 3Dept. of Neurology (BWH) and Headache & Face Pain Program, Brigham & Women’s Hospital Harvard Medical School and Tufts School of Dental Medicine, Boston, USA 4Eli Lilly and Company (retired), Indianapolis, USA 5Arteaus Therapeutics, Cambridge, USA

Published: 18 September 2014


© 2014 Goadsby et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.